Molecular mechanisms of cisplatin resistance in cervical cancer

Abstract

Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%–20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer.

α‐Mangostin attenuates stemness and enhances cisplatin‐induced cell death in cervical cancer stem‐like cells through induction of mitochondrial‐mediated apoptosis

“…Platinum‐based chemotherapy is the standard treatment for patients with advanced or recurrent cervical cancer who cannot be operated and irradiated (Leath & Straughn, 2013). However, cisplatin also has adverse side effects in patients with cancer, and the development of drug resistance limits its therapeutic effects (Shen, Pouliot, Hall, & Gottesman, 2012; Zhu et al, 2016). Cervical cancer patients with chemotherapy‐resistant and recurrent cancers usually have a very poor prognosis and low 5‐year survival rate (Li, Hu, Wang, & Yang, 2019).…”

Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines

“…Ratih Dewi Yudhani 1 *, Indwiani Astuti 2 , Mustofa Mustofa 2 , Dono Indarto 3 , Muthmainah Muthmainah 4 cells, E6 HPV protein enhances degradation of p53 protein through binding with leucine rich motifs of E6-associated protein in the ubiquitin ligase (Scheffner et al, 1993;Saha et al, 2012;Ajay et al, 2012;Martinez-Zapien et al, 2016). These protein binding complexes contribute in cisplatin resistance of some cancer cells including cervical cancer (Florea and Büsselberg, 2011;Yang-Hartwich et al, 2014;Zhu et al, 2016). Thus, restoration of p53 function is crucial in the management of HPV-associated cervical cancer because HeLa cells were treated with celecoxib (non-steroidal anti-inflammatory drug) could re-activate p53 via induction of ataxia telangiectasia mutated-/p38 mitogen-activated protein kinase and down regulation of cycloxygenase-2 (Saha et al, 2012).…”

<p>LncRNA miR503HG Regulates the Drug Resistance of Recurrent Cervical Squamous Cell Carcinoma Cells by Regulating miR-155/Caspase-3</p>

“…However, the development of chemoresistance is commonly seen, which could lead to poor survival. 9 Caspase-3 is a caspase protein that plays pivotal roles in cancer biology mainly by regulating cancer cell apoptosis. 10 It has been reported that the inhibition of caspase-3 is closely correlated with the development of drug resistance in cancer cells during chemotherapy.…”